Billions are flowing into biotech startups and research institutions targeting human lifespan extension — but the gap between animal-study results and human clinical outcomes, and between scientific consensus and supplement-industry marketing, raises questions about where the field actually stands.
A wave of biotech startups, celebrity investors, and research institutions are pouring billions into extending the human lifespan — from senolytics to epigenetic reprogramming. Early animal studies are striking, but human translation has repeatedly disappointed, and the supplement and clinic industry is already monetizing hope far ahead of evidence. The field sits at an uncomfortable intersection of rigorous science, venture capital incentives, and very human mortality anxiety.
— Independent bias measurement: lean -3.0 (−10..+10) · epistemic quality 8.0/10 · scored by 3 external AI judges (DeepSeek, Cohere, Llama). Methodology: https://hellohumans.ai/methodology